Arctic Therapeutics Initiates Phase IIa Trial of Novel Acetylcholinesterase Inhibitor AT-004 for Acne Vulgaris
Key Insights
Arctic Therapeutics (search) has enrolled the first patients in a Phase IIa randomized, double-blind, placebo-controlled trial evaluating topical AT-004 for acne vulgaris (search) treatment.
AT-004 represents a first-in-class acetylcholinesterase (search) inhibitor targeting the non-neuronal cholinergic anti-inflammatory pathway to modulate TNF-α (search) and reduce skin inflammation.
The 60-participant study will assess safety and efficacy over 12 weeks across three Danish clinical sites, with potential applications extending to other inflammatory skin conditions.
Arctic Therapeutics (search) has announced the enrollment of first patients in a Phase IIa clinical trial evaluating AT-004, a novel topical acetylcholinesterase (search) inhibitor, for the treatment of acne vulgaris (search). The randomized, double-blind, placebo-controlled study follows regulatory approval from the European Medicines Agency (search) in December 2025 and represents a significant milestone in developing a first-in-class therapeutic approach for inflammatory skin diseases.
Novel Mechanism Targets TNF-α Pathway
AT-004 represents an innovative approach to treating inflammatory skin diseases by targeting the non-neuronal cholinergic anti-inflammatory pathway present in human skin. This biological system regulates inflammation and pro-inflammatory cytokines such as TNF-α (search), offering a potentially first-in-class mechanism in dermatologic therapy. Preclinical and early clinical findings suggest AT-004 could deliver robust local anti-inflammatory effects without systemic exposure.
"As AT-004 targets a novel anti-inflammatory pathway in the skin, it represents a new approach to the treatment of inflammatory dermatologic conditions," said ATx founder Dr. Hakon Hakonarson. "While our current clinical focus is acne vulgaris (search), these findings suggest the mechanism underlying AT-004 could be relevant across a range of inflammatory skin diseases, including atopic dermatitis (search), psoriasis (search) and rosacea (search), warranting further clinical investigation."
Addressing Significant Global Disease Burden
Acne vulgaris (search) affects an estimated 650 million people worldwide and ranks among the most prevalent diseases across all age groups. While often associated with adolescence, acne frequently persists into adulthood and can have a significant impact on quality of life, contributing to anxiety, reduced self-esteem, and depression.
"AV affects hundreds of millions of people worldwide and is far more than a cosmetic condition," said Ivar Hakonarson, chief executive officer and co-founder of ATx. "The initiation of patient enrollment marks an important milestone for AT-004 as we work to advance a novel approach that has the potential to meaningfully improve outcomes for people living with this disease."
Phase IIa Study Design and Endpoints
The Phase IIa clinical trial will enroll 60 participants aged 18 to 45, randomized 1:1 to receive either AT-004 or placebo for a 12-week treatment period, with 30 participants in each arm. All enrolled participants will be included in the final analysis.
Safety assessments will include monitoring of adverse events, local skin reactions, physical examinations, vital signs, and clinical laboratory testing, including serum chemistry and hematology, as well as pregnancy testing for women of child-bearing potential. Clinical efficacy will be assessed using the Investigator's Global Assessment (IGA) scale in combination with lesion counts at baseline and at Weeks 4, 8, and 12.
The study will be conducted across three clinical sites in Denmark and is being carried out by Blueskin (search), a leading European contract research organization specializing in dermatology. Blueskin is part of the Sanos Group of companies, a multi-niche CRO with a strong track record in the design and execution of dermatology clinical trials.
Company Background
Arctic Therapeutics (search) is a clinical-stage biopharmaceutical company established in 2015 as a spin-off from the US-based Center for Applied Genomics, a research centre at the Children's Hospital of Philadelphia. The company has operations in Iceland, the US and multiple collaborations across Europe, with a diversified pipeline reflecting its commitment to address diseases with high unmet need.